Detailed Narrative
Q1 FY26 Performance Impacted by Seasonal Factors
Dabur India reported a consolidated sales growth of 1.7% for Q1 FY26, significantly impacted by unseasonal rains and a short summer. This adverse weather particularly affected the seasonal portfolio, leading to a ~30% decline in glucose sales. However, excluding the seasonal portfolio, consolidated sales growth stood at approximately 7%, indicating underlying business resilience despite these challenges.
Robust Domestic and International Business Growth
The international business demonstrated strong performance, growing 13.7% in constant currency and 12.7% in INR terms. Domestically, the HPC portfolio grew 5%, with the Toothpaste segment achieving 7.3% growth, driven by the Red franchise. The Home Care portfolio also delivered robust growth of 10%, with Odonil emerging as the #1 brand in air fresheners with a 44% volume market share, and Odomos showing double-digit growth.
Strong Market Share Gains Across Key Categories
Dabur achieved notable market share gains in several core categories. Hair Oil saw a 214 bps gain, reaching 19% volume market share. In the Healthcare portfolio, Chyawanprash grew 28% and gained 111 bps market share, while Honey grew 11% with a 46 bps market share gain. The J&N segment also outperformed, gaining 207 bps in nectars and 141 bps in 100% juices, reinforcing the company's competitive position.
Profitability Maintained Amidst Inflation and Competition
Despite high inflation and competitive intensity, Dabur's operating profit and PAT grew ahead of the topline. Management noted that IGAAP gross margins remained stable, but competitive pressures, particularly from Colgate in Toothpaste and Hair Oils, led to higher netting of schemes (BTL), impacting Ind AS gross margins. The company has implemented 3-4% price increases and saving initiatives to mitigate a projected 8% inflation going forward⏳, aiming to protect margins.
Strategic Focus on Core Brands and Portfolio Modernization
Dabur outlined a strategic framework focusing on doubling down on core brands, contemporizing Dabur Amla, and expanding the home care segment. In Healthcare, four brands—Pudin Hara, Health Juices, Hajmola, and Shilajit—are targeted for significant scaling, with Hajmola aiming for Rs. 550 crores and the others for Rs. 100 crores each. The company is also actively scouting for new-age, margin-accretive M&A targets in wellness, health, and premium segments to fortify its portfolio.
Outlook for Q2 FY26 and Full Year FY26
For Q2 FY26, Dabur anticipates achieving double-digit growth, with other verticals expected to fire at double digits, although the beverage business is projected to see only low single-digit growth. For the full fiscal year 2025-26, the company is targeting high single-digit growth. Management is committed to ensuring that operating margins 'inch up significantly' compared to the previous year, driven by premiumization and a better product mix.